Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 20/20 | 0.58 |
| ▸ | JAK1 | P23458 | 20/20 | 0.58 |
| ▸ | TYK2 | P29597 | 20/20 | 0.58 |
| ▸ | JAK3 | P52333 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883629 | 0.85 | NPC1 (0.50) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL12699179 | 0.83 | JAK2 (0.56) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL11300658 | 0.83 | EPHB3 (0.55) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920353 | 0.82 | JAK2 (0.54) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL12493990 | 0.82 | JAK2 (0.54) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15883632 | 0.78 | ALDH1A1 (0.56) | — | |
| SCHEMBL9920282 | 0.77 | JAK2 (0.58) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL9920205 | 0.76 | JAK2 (0.78) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL21083418 | 0.75 | EPHB3 (0.55) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL15883633 | 0.75 | MAP4K4 (0.47) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102570-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-2685982-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9586969-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-03-07 | — | — | US | disclosed |
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-08 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011014817-A1 | PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 10/4885 |
| US-20160355518-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C3AR1 | JAK2 1763/4885JAK1 1559/4885TYK2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.